The 4 Wall Street analysts covering Mobia Medical, Inc. hold a median 12-month price target of $18 — +70.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Mobia Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (73): Analysts have, on balance, been raising their forecasts.
Quality (0): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MOBI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +70.1% from it.
Of the 17 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | BTIG | Reiterates | Buy | $19 |
| 12 Aug 2026 | BTIG | Reiterates | Buy | $19 |
| 12 Aug 2026 | BTIG | Reiterates | Buy | — |
| 12 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 12 Aug 2026 | JP Morgan | Maintains | Overweight | $15 → $17 |
| 2 June 2026 | B of A Securities | Initiates | Buy | — |
| 2 June 2026 | B of A Securities | Initiates | Buy | $16 |
| 2 June 2026 | BTIG | Initiates | Buy | — |
| 2 June 2026 | BTIG | Initiates | Buy | $19 |
| 2 June 2026 | Goldman Sachs | Initiates | Buy | $31 |
| 2 June 2026 | Goldman Sachs | Initiates | Buy | — |
| 2 June 2026 | JP Morgan | Initiates | Overweight | $15 |
| 2 June 2026 | JP Morgan | Initiates | Overweight | — |
| 26 Feb 2015 | Rosenblatt | Initiates | Buy | $10 |
| 4 Feb 2013 | Piper Sandler | Maintains | Overweight | $2.94 → $2.70 |
| 12 Nov 2012 | Piper Sandler | Maintains | Overweight | $3.20 → $2.94 |
| 14 Aug 2012 | Piper Sandler | Maintains | Overweight | $7.00 → $3.20 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MOBI appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 16% of US stocks
Cheaper than 42% of US stocks
Cheaper than 77% of US stocks
Higher than 92% of US stocks
Higher than 93% of US stocks
Higher than 12% of US stocks
Higher than 4% of US stocks
Higher than 88% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Mobia Medical, Inc. has a market value of $352.2M and an enterprise value of $183.6M.
Revenue in the twelve months to 30 June 2026: $37.9M. The latest quarter grew 102.4% year on year.
Net income over the same four quarters: −$59.9M, a −158.1% net margin.
Diluted earnings per share, trailing twelve months: $−2.55.
Free cash flow in the twelve months to 30 June 2026: −$55.7M.
Trailing P/E: −526.5×; forward P/E: −4.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Mobia Medical, Inc. employs 167 people — $227K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Mobia Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Mobia Medical announced it will report third-quarter 2026 financial results on November 5, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update.
Why it matters — MOBI watchers can note the date and time when the company plans to share its quarterly results and corporate update.
Mobia Medical announced that implantable paired Vagus Nerve Stimulation (VNS) has been recognized in the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery, published August 27, 2026, as a treatment option to improve upper-limb function and impairment for chronic stroke survivors.
Why it matters — This recognition in an official AHA/ASA stroke rehabilitation guideline could increase awareness and adoption of Mobia's VNS technology among stroke rehabilitation providers.
Mobia Medical, Inc. (MOBI) held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's second-quarter 2026 financial results and associated discussion.
Why it matters — Investors and analysts following MOBI would review the earnings call transcript for details on the company's second-quarter 2026 financial performance and management commentary.
Mobia Medical reported second-quarter revenue of $13.5 million, up 102% from $6.7 million a year earlier, driven by expanded adoption of its Vivistim paired vagus nerve stimulation therapy across new and existing stroke-care programs as discussed in its Q2 earnings call.
Why it matters — For MOBI watchers, the 102% revenue growth signals strong uptake of the Vivistim therapy across expanded stroke-care programs.
Mobia Medical reported financial results for the quarter ended June 30, 2026, with revenue of $13.5 million representing 102% year-over-year growth and a gross margin of 83.2%. The company also announced publication of two-year VNS-REHAB follow-up data in Neurology, completed its initial public offering with approximately $134.0 million in net proceeds, and appointed Myriam Curet, M.D.
Why it matters — The quarterly update provides MOBI watchers with the company's revenue growth, margin performance, and clinical data milestones as a newly public medical device company.
The 4 Wall Street analysts covering Mobia Medical, Inc. have a median 12-month price target of $18, with estimates ranging from $16 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Mobia Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mobia Medical, Inc. 3 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Mobia Medical, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (73 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +70.1% from the last close, and Ticker Nerd's factor model ranks Mobia Medical, Inc. 3 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Mobia Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MOBI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $19 over the next 12 months.
Mobia Medical, Inc. is a commercial-stage medical device company focused on neurostimulation solutions for neurological rehabilitation.
The most recent item we track (GlobeNewsWire, 15 Oct 2026): "Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026". Mobia Medical announced it will report third-quarter 2026 financial results on November 5, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update.
Mobia Medical, Inc. is a commercial-stage medical device company focused on neurostimulation solutions for neurological rehabilitation. Its flagship Vivistim Paired Vagus Nerve Stimulation system is an FDA-approved implantable therapy designed to support upper limb motor recovery in people living with chronic ischemic stroke and related motor impairments. The company develops, markets, and sells devices that combine vagus nerve stimulation with structured therapy to promote neuroplasticity and functional improvement. Mobia Medical serves stroke centers and healthcare providers involved in post-stroke rehabilitation, with its products positioned within the medical devices sector as specialized tools for chronic neurological care. Founded in 2007 and headquartered in Austin, Texas, Mobia Medical plays a focused role in the recovery technology market by offering clinically validated treatment options for patients with persistent movement limitations.
CEO Mr. Richard John Foust · 167 employees · United States · https://www.mobia.com
